Figure 2
From: Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma
Expression of SLLP1 correlates with a worse prognosis in patients treated with alloSCT. A total of 84 patients who had received alloSCT were divided into to two groups according to the SLLP1 expression status in their bone marrow as determined by RT-PCR. Curves represent Kaplan–Meier estimates of progression-free survival (a) and overall survival (b) from application of alloSCT until end of observation.